Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Allergy & Immunology
•
Asthma
Do you utilize urinary leukotrienes as a marker for initiation of montelukast?
Answer from: at Academic Institution
No, I don’t. It is not readily available clinically and has not been shown to be predictive of response.
Sign in or Register to read more
23597
Related Questions
What is your preferred biologic in children and adolescents with T2 high asthma?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
When would you recommend prescribing an asthmatic patient budesonide/salbutamol rather than budesonide/formoterol?
How do you decide when to add a second biologic agent to a patient’s asthma treatment who has either not responded or had a partial response to dupilumab, omalizumab, mepolizumab, or tezepelumab?
How do you factor smoking history into biologic selection for asthma since the clinical trials generally excluded these patients?
Have you observed adverse mental health side effects in patients who start montelukast?
Is methacholine challenge on its way out?
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
What is your preferred biologic for an asthmatic patient with a T2 low phenotype and who is a smoker?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?